| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ligustrosidic acid interacts with biological pathways that exhibit anti-inflammatory and antioxidative properties, helping to modulate oxidative stress and inflammatory responses. Its mode of action involves targeting pathways implicated in various pathophysiological conditions. The compound's carboxyl moiety may influence target binding interactions compared to its methyl ester analog.
|
|---|---|
| ln Vitro |
In vitro, ligustrosidic acid exhibits hepatoprotective activity and superior cytoprotection in cellular models. It demonstrates antioxidant and anti-inflammatory properties. The compound's biological activity has been shown in a variety of studies. Its distinct analytical detection properties (HPLC retention shift) and ionization efficiency in MS have been characterized.
|
| ln Vivo |
In vivo studies on ligustrosidic acid are limited. Based on its anti-inflammatory and antioxidative properties, the compound may have potential therapeutic effects in managing conditions such as inflammatory disorders and cardiovascular diseases. Its hepatoprotective activity suggests potential in liver disease research. Further in vivo studies are needed to fully characterize its pharmacological effects.
|
| Enzyme Assay |
For in vitro antioxidant assays, ligustrosidic acid can be evaluated using DPPH or ABTS radical scavenging assays. The compound is incubated with radical solutions, and the decrease in absorbance is measured. Scavenging activity is calculated as a percentage. Anti-inflammatory activity can be assessed by measuring inhibition of pro-inflammatory cytokine production in stimulated cells.
|
| Cell Assay |
For in vitro cell-based assays, ligustrosidic acid is typically tested on hepatocytes or other cell lines for cytoprotective effects. Cells are treated with the compound at various concentrations (typically 1-100 μM) in the presence or absence of cytotoxic stimuli. Cell viability is assessed using MTT or CCK-8 assays. Inflammatory cytokine production is measured by ELISA. Signaling pathway modulation is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for ligustrosidic acid have not been extensively reported. Based on its hepatoprotective and anti-inflammatory activities, potential experimental models include liver injury models and inflammation models in mice or rats. The compound could be administered orally or intraperitoneally, with liver function parameters or inflammatory markers assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ligustrosidic acid are limited. As a secoiridoid glycoside with a molecular weight of 554.50 g/mol and formula C₂₅H₃₀O₁₄, it is expected to have moderate oral bioavailability. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for ligustrosidic acid are limited. As a natural product isolate, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
According to reports, Japanese privet and glossy privet contain privetine, and relevant data are available for reference.
Ligustrosidic acid is a research-use only compound and has not been approved for clinical applications. It is a secoiridoid glycoside from Ligustrum japonicum and Ligustrum lucidum. Its molecular weight is 554.50 and formula is C₂₅H₃₀O₁₄. The compound is available from various research chemical suppliers. |
| Molecular Formula |
C25H30O14
|
|---|---|
| Molecular Weight |
554.497309207916
|
| Exact Mass |
554.163
|
| CAS # |
96382-89-7
|
| PubChem CID |
146014676
|
| Appearance |
Off-white to light yellow solid
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
39
|
| Complexity |
924
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC(=O)C1=COC(/C(=C/C(=O)O)/C1CC(=O)OCCC2=CC=C(C=C2)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
DJAAGTPILCOZIR-MSISIIAVSA-N
|
| InChi Code |
InChI=1S/C25H30O14/c1-35-23(34)16-11-37-24(39-25-22(33)21(32)20(31)17(10-26)38-25)15(8-18(28)29)14(16)9-19(30)36-7-6-12-2-4-13(27)5-3-12/h2-5,8,11,14,17,20-22,24-27,31-33H,6-7,9-10H2,1H3,(H,28,29)/b15-8+/t14?,17-,20-,21+,22-,24?,25+/m1/s1
|
| Chemical Name |
(2E)-2-[4-[2-[2-(4-hydroxyphenyl)ethoxy]-2-oxoethyl]-5-methoxycarbonyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-ylidene]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~180.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8034 mL | 9.0171 mL | 18.0343 mL | |
| 5 mM | 0.3607 mL | 1.8034 mL | 3.6069 mL | |
| 10 mM | 0.1803 mL | 0.9017 mL | 1.8034 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
